Quick Facts

• Therapeutic Domain: Management of abnormal lipid levels.
• Primary Uses: Adjunct to diet for hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.
• Associated Benefit: Supports a reduction in cardiovascular risk.

Lipicard-AV is a prescription medication utilized in adults as an adjunct to diet and lifestyle modification to support the management of elevated lipid parameters in the blood. The drug is indicated for individuals requiring intervention for conditions such as primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia, where elevated lipid levels may contribute to potential health concerns.

The therapeutic purpose of this medication is to help reduce the level of low-density lipoprotein cholesterol (LDL-C, or 'bad cholesterol'), total cholesterol, and triglycerides (fats) circulating in the bloodstream. Furthermore, its components work to assist in the increase of high-density lipoprotein cholesterol (HDL-C, or 'good cholesterol'). Achieving acceptable lipid parameters is a key step in reducing the risk of certain cardiovascular events, which is an important aspect of a comprehensive treatment plan for dyslipidemia. It may be used to reduce the risk of non-fatal myocardial infarction, stroke, and certain revascularization procedures in adults with multiple risk factors or clinically evident coronary heart disease (CHD). The full treatment program requires commitment to diet, physical activity, and weight management.

Regulatory References

1. NIH MedlinePlus guidance on fenofibrate and atorvastatin

Official Regulatory Eligibility for Lipicard-AV

Lipicard-AV is generally approved for use in adults (18 years of age and older). The eligibility profile is strictly defined by the combination of contraindications for its two components, Atorvastatin and Fenofibrate.

Category	Regulatory Status
Populations for whom use is allowed (as stated in label):	Adults with mixed dyslipidemia whose lipid levels are inadequately controlled by statin monotherapy.
Populations for whom use is contraindicated:	Individuals with active liver disease (including unexplained persistent transaminase elevations), severe renal impairment (eGFR <30 mL/min/1.73 m^2), pre-existing gallbladder disease, or known hypersensitivity to any component.
Pregnancy and lactation eligibility status:	Contraindicated in pregnancy and lactation/breastfeeding. Women of childbearing potential are advised to use effective contraception during treatment.
Age-related eligibility rules:	Not recommended for use in children and adolescents (under 18 years of age) as safety and efficacy data are not established for the combination product. Older adults may require caution due to increased risk factors.
Condition-specific eligibility restrictions:	Restricted use and close monitoring are necessary for patients with uncontrolled hypothyroidism or moderate renal impairment (e.g., eGFR 30 to <60 mL/min/1.73 m^2), as these conditions increase the risk of adverse effects.

Official regulatory documents define non-eligibility by listing specific, absolute criteria tied to organ function, reproductive status, and allergic history. The medicine is prohibited for populations with these formal contraindications, which are derived from the risk profiles of both the statin and fibrate components.

The official regulatory profile for Lipicard-AV (Atorvastatin/Fenofibrate) defines specific interaction patterns that can significantly alter drug exposure or increase toxicity risk, requiring formal restrictions.

Contraindicated Combinations

Co-administration is explicitly prohibited with strong inhibitors of the enzyme CYP3A4, such as Ciclosporin, or specific combinations of HIV/HCV antivirals, including Glecaprevir/Pibrentasvir. The fenofibrate component is contraindicated with other fibric acid derivatives like Gemfibrozil, due to the formally documented high risk of myopathy and rhabdomyolysis.

---

Pharmacodynamic and Exposure Alterations

Strong CYP3A4 inhibitors, such as Clarithromycin and Itraconazole, increase the plasma concentrations of Atorvastatin, necessitating restrictions on the maximum dose permitted. The fenofibrate component may potentiate the effect of oral coumarin anticoagulants (e.g., Warfarin), a pharmacodynamic interaction that requires the formal monitoring of the International Normalized Ratio (INR). Certain agents, including Colchicine or Niacin (geq 1 g/day), increase the documented risk of skeletal muscle effects when combined with the statin component.

---

Administration Timing and Other Substances

To prevent absorption interference, the fenofibrate component requires mandatory separation from bile-acid binding resins by administering the medicine at least one hour before or four to six hours after the resin. Consumption of large quantities of Grapefruit Juice is documented to increase the systemic exposure of Atorvastatin. The overall interaction risk is noted to be heightened in populations with renal impairment.

How Lipicard-AV Works: Mechanism of Action

Lipicard-AV's action is achieved through two distinct, coordinated mechanisms that target the core processes of lipid production and clearance.

Inhibition of Cholesterol Synthesis

The Atorvastatin component acts by competitively inhibiting the HMG-CoA reductase enzyme, which is the critical, rate-limiting step in the liver's mevalonate pathway for manufacturing cholesterol. This targeted blockade leads to a diminished internal cholesterol pool, which triggers the liver to up-regulate (increase) the number of extbfLDL extbfreceptors on its cell surface. The resulting physiological effect is an acceleration of plasma LDL-C clearance from the bloodstream.

PPARalpha Modulation of Triglyceride Catabolism

The Fenofibrate component works by acting as an agonist for the nuclear receptor Peroxisome Proliferator-Activated Receptor alpha (, PPARalpha). This activation alters genetic transcription to boost factors like extbflipoprotein lipase (, LPL) and reduce factors that inhibit fat breakdown, like extbfApolipoprotein C-III. This molecular change accelerates the breakdown and removal (catabolism) of triglyceride-rich VLDL and chylomicrons, resulting in the physiological consequence of reduced plasma triglyceride concentration.

How to Use Lipicard-AV

Lipicard-AV is a fixed-dose combination (FDC) medicine containing Atorvastatin and Fenofibrate. Its proper use is governed by instructions concerning the method, frequency, timing, and specific circumstances of administration.

---

Official Administration Guidelines

The following instructions detail how the tablet is administered, serving as a standardized protocol for its use.

Instruction Domain	Requirement
Route and Form	Must be administered orally as a whole tablet. The tablet should not be crushed, broken, or chewed.
Dosing Frequency	The medicine is taken once daily (OD).
Timing and Food	Can be taken at any time of the day, and intake is permitted with or without food.
Missed Dose Rule	If a dose is missed, do not take an extra dose to compensate. Resume the regular schedule with the next planned daily dose.

---

Population and Procedural Constraints

Specific conditions govern the drug's use in certain situations:

• Pediatric Use: The combination product is not generally recommended for use in children and adolescents under 18 years of age.
• Concomitant Medication: If a patient is taking a bile acid-binding resin (e.g., cholestyramine), the Lipicard-AV tablet must be administered at least 1 hour before or 4 to 6 hours after the resin to prevent interference with absorption.

This regimen establishes a standardized protocol for the chronic management of abnormal lipid levels as an adjunct to diet, requiring patient adherence to the once-daily oral route for correct systemic delivery.

Research Evidence: Overview of Studies for Lipicard-AV

---

Evidence for Management of Mixed Dyslipidemia

Research exploring Lipicard-AV has primarily studied how the combination is associated with the different types of fats, or lipids, found in the blood. Studies for this use are generally short-term randomized controlled trials (RCTs) involving adults with mixed dyslipidemia (elevated LDL-C and triglycerides). These studies examined differences when the fixed-dose combination was used against the statin component alone. Researchers monitored shifts in key lipid biomarkers such as non-HDL cholesterol and triglycerides. Because these trials typically last only a few months, the long-term effects on the maintenance of these lipid changes are not fully established.

---

Evidence Related to Cardiovascular Risk Reduction

Research examined patterns related to major clinical events, such as a non-fatal heart attack or stroke. Dedicated long-term RCTs for this specific fixed-dose combination are not widely available. Instead, the evidence draws information from large-scale trials that studied the individual components (statin and fibrate) and performed subgroup analyses. These analyses examined the incidence of Major Adverse Cardiovascular Events (MACEs) in adults with established heart disease or specific lipid profiles like atherogenic dyslipidemia. The certainty remains low regarding the direct, long-term impact of the Lipicard-AV fixed-dose combination itself on the incidence of these clinical events, as the evidence is largely indirect.

---

Evidence in Specific Patient Groups and Limitations

The research primarily focused on a broad population of adults, including those with conditions like Type 2 Diabetes Mellitus (T2DM) who also had abnormal lipid levels. Data for certain other groups, such as children or pregnant individuals, remain insufficient. The available evidence landscape highlights key limitations: the follow-up durations for lipid-change studies were short, and there is a relative absence of dedicated, long-term clinical outcome trials for the fixed-dose combination.

Key Studies & References Fenofibrate and Atorvastatin Oral: MedlinePlus Drug Information

Common questions about Lipicard-AV (FAQ)

Q: How should I store Lipicard-AV tablets at home?

Official regulatory documents advise storing Lipicard-AV in its original, closed container at a controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medicine should be protected from excessive heat, moisture, and direct light, as required by the product label. For safety, the tablets must be kept out of the sight and reach of children and pets.

---

Q: What is the primary benefit of taking both atorvastatin and fenofibrate together?

According to the official product information, the primary benefit of this combination medicine is the comprehensive management of mixed dyslipidemia. This condition involves having abnormal blood lipid levels, specifically elevated low-density lipoprotein cholesterol (LDL-C) and elevated triglycerides. The two components work together as an adjunct to diet when statin-alone therapy has not been sufficient to reach specific lipid goals.

---

Q: What kind of clinical trial evidence supports the use of Lipicard-AV?

Clinical studies have shown that the combination is associated with positive changes in lipid biomarkers, such as lowering LDL-C and triglycerides, in adults with mixed dyslipidemia. While these studies assessed its effect on blood lipid levels, the long-term evidence regarding the reduction of major clinical events like heart attack or stroke is often indirect, drawn primarily from large-scale trials of the individual components.

---

Q: Is Lipicard-AV a brand name or a generic drug?

Lipicard-AV is a brand name for a fixed-dose combination product. It contains two distinct active ingredients: the cholesterol-lowering agent Atorvastatin and the triglyceride-lowering agent Fenofibrate. This single tablet contains a specific dosage of both these drugs.

---

Q: Does Lipicard-AV require a prescription?

Yes, Lipicard-AV is a prescription-only medicine. This requirement is noted on the official drug labeling, often identified with the regulatory designation Rx Only.

How to Store and Dispose of Lipicard-AV?

Strict adherence to official storage and disposal requirements is necessary to maintain the quality and integrity of Lipicard-AV tablets (Atorvastatin/Fenofibrate).

---

Official Storage Requirements

Requirement	Condition
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environment	Keep away from excessive heat, moisture, and direct light. Do not freeze.
Packaging	Must remain in its original, closed container until the time of use.
Safety	Mandatory requirement: Keep out of the sight and reach of children and pets.

---

Official Disposal Instructions

Unused or expired Lipicard-AV must not be disposed of in household trash or flushed down a toilet. Instead, disposal must follow professional or local controlled-waste requirements. Consult a healthcare professional or pharmacist for instructions on proper disposal.